IP Library Granted Patent US 9,790,504
Granted Patent B2
US 9,790,504 · App. 14/893,690 · Granted Oct 17, 2017

Anti-tumor therapy

Inventors: Nikolai Khodarev (Villa Park, IL); Ravi Sood (Seattle, WA); Bernard Roizman (Chicago, IL); Ralph R. Weichselbaum (Chicago, IL)
Assignee: The University of Chicago
C12N15/1137A61K31/506A61K31/519A61K31/713A61K45/06C12N15/113C12Q1/6886C12N2310/14C12N2320/12C12N2320/30C12Q2600/136C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,790,504
App. No.
14/893,690
Granted
Oct 17, 2017
Kind
B2
Abstract

Panels, compositions, and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.

Claims (7)

1. A method of treating cancer in a subject by increasing the sensitivity of tumor cells of the subject to radiotherapy comprising:

a) administering to the tumor cells a siRNA or shRNA that directly targets DHX58 mRNA in an amount that is sufficient to suppress expression of the DHX58 gene thereby increasing the sensitivity of the cells to radiotherapy; and

b) administering to the subject a therapeutically effective amount of radiotherapy.

2. The method of claim 1 further comprising administration to the subject a therapeutically effective amount of at least one of a Jak2 or a Jak1/Jak2 inhibitor.

3. The method of claim 1 wherein DHX58 mRNA is decreased by at least 25% in tumor cells, compared to untreated cells of the same tumor.

4. The method of claim 1 , wherein the radiotherapy comprises at least one of brachytherapy, external beam radiation therapy, or radiation from cesium, iridium, iodine, or cobalt.

5. The method of claim 1 further comprising administering to the tumor cells a siRNA or shRNA that directly targets mRNA of a gene selected from the group consisting of PLSCR1, USP18, PSMB10, IFITM1, OASL, EPSTL1, LGALS3BP, IFIH1, ABCC3, DTX3L, PSMB9, IRF9, TAGLN, IFIT2, TPD52L1, CXCL9, GBP1, BST2, SP110, HERC5, CCL2, WARS, MCL1, and TRIM14.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 30, 2015
From: WEICHSELBAUM, RALPH; ROIZMAN, BERNARD; KHODAREV, NIKOLAI; SOOD, RAVI
To: THE UNIVERSITY OF CHICAGO
Reel/Frame 037382/0736 →
Continuity (2)
Provisional Application 61827402 · May 24, 2013
Related Publication 20160222387A1 · Aug 4, 2016